Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05 2022 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq: CARA), an early
commercial-stage biopharmaceutical company leading a new treatment
paradigm to improve the lives of patients suffering from pruritus,
today announced that Christopher Posner, President and Chief
Executive Officer, will participate in a fireside chat at the 21st
Annual Needham Virtual Healthcare Conference on Monday, April 11,
2022, at 1:30 p.m. ET.
A webcast of the fireside chat can be accessed
under "Events & Presentations" in the News & Investors
section of the Company's website at www.CaraTherapeutics.com. An
archived webcast recording will be available on the Cara website
for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is an early commercial-stage
biopharmaceutical company leading a new treatment paradigm to
improve the lives of patients suffering from pruritus. The
Company’s novel KORSUVA™ (difelikefalin) injection is the first and
only FDA-approved treatment for moderate-to-severe pruritus
associated with chronic kidney disease in adults undergoing
hemodialysis. The Company is developing an oral formulation of
difelikefalin and has initiated Phase 3 programs for the treatment
of pruritus in patients with non-dialysis dependent advanced
chronic kidney disease and atopic dermatitis. Phase 2 trials of
Oral KORSUVA (difelikefalin) are ongoing in primary biliary
cholangitis and notalgia paresthetica patients with
moderate-to-severe pruritus. For more information, visit
www.CaraTherapeutics.com and follow the company on Twitter,
LinkedIn and Instagram.
MEDIA CONTACT:Annie Spinetta6
Degrees973-768-2170aspinetta@6degreespr.com
INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara
Therapeutics203-406-3700investor@caratherapeutics.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024